Details of the Drug
General Information of Drug (ID: DMI6P91)
Drug Name |
1-Methyl-1,2,3,4-tetrahydro-isoquinoline-6,7-diol
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
1-methyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol; 525-72-4; (+/-) Salsolinol; CHEMBL416732; 1-Methyl-6,7-dihydroxytetrahydroisoquinoline; CHEBI:88801; (R)-Salsolinol; IBRKLUSXDYATLG-UHFFFAOYSA-N; 1-Methyl-1,2,3,4-tetrahydro-isoquinoline-6,7-diol; 6,7-Isoquinolinediol, 1,2,3,4-tetrahydro-1-methyl-; 1-Methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline; Sasolinol; (+)-Salsolinol; (R)-(+)-Salsolinol; (+)-(R)-Salsolinol; AC1L1H1L; Oprea1_470083; SCHEMBL1627427; CTK4J6115; 1,2,3,4-TETRAHYDRO-1-METHYL-6,7-ISOQUINOLINEDIOL
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 179.22 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 1 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 0 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 3 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||